| Literature DB >> 32609846 |
Ashley Cartwright1, Simon J Webster1, Annika de Jong2, Richard J Dirven2, Lisa D S Bloomer1, Ahlam M Al-Buhairan1, Ulrich Budde3, Christer Halldén4, David Habart5, Jenny Goudemand6, Ian R Peake1, Jeroen C J Eikenboom2, Anne C Goodeve1, Daniel J Hampshire7.
Abstract
Copy number variation (CNV) is known to cause all von Willebrand disease (VWD) types, although the associated pathogenic mechanisms involved have not been extensively studied. Notably, in-frame CNV provides a unique opportunity to investigate how specific von Willebrand factor (VWF) domains influence the processing and packaging of the protein. Using multiplex ligation-dependent probe amplification, this study determined the extent to which CNV contributed to VWD in the Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease cohort, highlighting in-frame deletions of exons 3, 4-5, 32-34, and 33-34. Heterozygous in vitro recombinant VWF expression demonstrated that, although deletion of exons 3, 32-34, and 33-34 all resulted in significant reductions in total VWF (P < .0001, P < .001, and P < .01, respectively), only deletion of exons 3 and 32-34 had a significant impact on VWF secretion (P < .0001). High-resolution microscopy of heterozygous and homozygous deletions confirmed these observations, indicating that deletion of exons 3 and 32-34 severely impaired pseudo-Weibel-Palade body (WPB) formation, whereas deletion of exons 33-34 did not, with this variant still exhibiting pseudo-WPB formation similar to wild-type VWF. In-frame deletions in VWD, therefore, contribute to pathogenesis via moderate or severe defects in VWF biosynthesis and secretion.Entities:
Year: 2020 PMID: 32609846 PMCID: PMC7362359 DOI: 10.1182/bloodadvances.2018027813
Source DB: PubMed Journal: Blood Adv ISSN: 2473-9529